FDA Approves Ascendis' Yuviwel for Kids with Dwarfism

In a major win for families dealing with achondroplasia, the FDA has approved Ascendis Pharma's Yuviwel as a once-weekly treatment to help children grow taller.

This groundbreaking therapy, known generically as navepegritide, targets kids aged 2 and older with open growth plates, offering a simpler alternative to daily injections. The approval, granted on February 27, 2026 under the accelerated program, stems from a 52-week study showing significant gains in annualized growth velocity compared to placebo.

Also Read: How Digital Maturity is Powering Pharma's GMP Evolution

Achondroplasia, the most common form of short-limbed dwarfism, affects about one in every 15,000 to 40,000 newborns due to a mutation in the FGFR3 gene. Yuviwel works by delivering sustained levels of C-type natriuretic peptide, which counters the mutation's effects on bone growth.

Until now, the only approved option was BioMarin's Voxzogo, a daily shot that some patients—around 20%—don't respond well to. Experts see Yuviwel as a game-changer, potentially capturing market share with its easier dosing schedule that could boost adherence and improve quality of life.

Ascendis plans to roll out the drug in the US early in the second quarter of 2026, making it available through doctors with support from the company's Signature Access Program. This includes insurance navigation and financial aid for eligible families. Analysts project peak sales could hit around 772 million euros by 2032, highlighting the therapy's strong commercial promise. As the first treatment to provide continuous CNP exposure over a week, it marks a real step forward in managing this rare condition.